FindTrial
Sign In

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03564964
Acronym
SUVN-502
Enrollment
Unknown
Registered
2018-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2020-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Cognition Disorders, Dementia

Keywords

SUVN-502, Expanded Access

Brief summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.

Interventions

DRUGSUVN-502

Tablet

Sponsors

Suven Life Sciences Limited
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years

Inclusion criteria

* Subjects who have completed the 30 week treatment period of study CTP2S1502HT6 as planned and wish to continue treatment with SUVN-502. * Subject (or subject's legally acceptable representative) and caregiver must sign the Informed Consent Form (ICF) to participate in the study.

Exclusion criteria

* Has participated or is participating in any other clinical (investigational) study after completion of CTP2S1502HT6 study. * Is treated or likely to require treatment during the study with any medication prohibited by this expanded access program.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026